NewAmsterdam Pharma Company N.V. Warrant (NAMSW)

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

NewAmsterdam Pharma reported Q2 2025 earnings with $19.1 million in revenue, exceeding consensus estimates. The company showed progress in clinical trials for obicetrapib, a cholesterol-lowering therapy, and maintained strong cash reserves while preparing for potential European market entry.

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma announced positive results from a pre-specified Alzheimer's disease biomarker analysis in its Phase 3 BROADWAY trial, showing statistically significant reductions in key biomarkers in both the full study population and in ApoE4 carriers. The findings support the potential of obicetrapib, a CETP inhibitor, to prevent Alzheimer's disease progression.